1 |
Gulam Muhammad Khan RKT, Dewashish Singh Adhikari, Muna Rajbhandari, et al (2013). Evaluation of cancer prevalence and cytotoxic medication prescribing in central region of Nepal. Kathmandu University, J Sci Eng Technol, 9, 189-99.
|
2 |
Health MSf (2007). Drug use evaluation. in the & R. P. M. P. Program (Eds.), Drug and therapeutics committee. Training Course (pp. 1-9). United States: Management Sciences for Health.
|
3 |
Jindapol N., K. P. e. a. (2014). Crisis of health insurance under Thai civil servant medical benefit scheme (CSMBS). Srinagarin Med J, 9, 199-206.
|
4 |
Joerger M, Schaer-Thuer C, Koeberle D, et al (2014). Off-label use of anticancer drugs in eastern Switzerland: a populationbased prospective cohort study. Eur J Clin Pharmacol, 70, 719-25.
DOI
|
5 |
Kahan NR., Waitman DA, Blackman S, Vardy DA (2010). Drug use evaluation of tamoxifen focusing on off-label use in a managed care population in Israel. J Manag Care Pharm, 16, 355-9.
|
6 |
Keating GM (2009). Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. Drugs, 69, 1681-705.
DOI
|
7 |
Krzyzanowska MK (2013). Off-label use of cancer drugs: a benchmark is established. J Clin Oncol, 31, 1125-7.
DOI
|
8 |
Lee R J, Armstrong AC, Wardley AM (2012). Letrozole: advancing hormone therapy in breast cancer. Womens Health (Lond Engl), 8, 611-8.
DOI
|
9 |
Lerose R, Musto P, Aieta M, Papa C, Tartarone A (2012). Offlabel use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur J Clin Pharmacol, 68, 505-12.
DOI
|
10 |
Tartarone A, Lerose R, Aieta M (2012). Reflections about offlabel use of anticancer drugs. Ther Drug Monit, 34, 604.
|
11 |
Wang W, Zhu M, Guo D, et al (2013). Off-label and off-NCCN guidelines uses of antineoplastic drugs in China. Iran J Public Health, 42, 472-9.
|
12 |
World Health Organization (2002). Promoting rational use of medicine: core component. Retrieved from http://apps.who.int/medicinedocs/pdf/h3011e/h3011e.pdf.
|
13 |
Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor V (2007). Results of letrozole in postmenopausal women after tamoxifen treatment for advanced breast cancer. J Cancer Res Ther, 3, 71-4.
DOI
|
14 |
Cohen MH, Johnson JR, Justice R, Pazdur R (2011). Approval summary: letrozole (Femara(R) tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval. Oncologist, 16 1762-70.
DOI
|
15 |
Aphinive P, Vachirodom D, Thanapaisal C, Rangsrikajee D Somintara O (2014). Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy. Breast Cancer, 6, 145-150.
|
16 |
Barnadas A, Estevez LG, Lluch-Hernandez A, Rodriguez- Sanchez C, Sanchez-Rovira P (2011). An overview of letrozole in postmenopausal women with hormoneresponsive breast cancer. Adv Ther, 28, 1045-58.
DOI
|
17 |
Bundred NJ (2006). Letrozole: a well-tolerated and effective treatment for breast cancer. Womens Health, 2, 673-85.
|
18 |
Delpeuch A, Leveque D, Rob L, Bergerat JP (2011). Off-label use of oxaliplatin in patients with metastatic breast cancer. Anticancer Res, 31, 1765-7.
|
19 |
Gelmon K (2007). Prescribing extended adjuvant letrozole. Breast, 16, 446-55.
DOI
|
20 |
Goss PE (2007). Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat, 105, 45-53.
|
21 |
National List of Essential Medicines. (2009). National list of essential medicines Thailand 2009. Retrieved from http://drug.fda.moph.go.th:81/nlem.in.th/node/10351.
|
22 |
Mann BS, Johnson JR, Kelly R, et al (2005). Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res, 11, 5671-7.
DOI
|
23 |
Nabholtz JM, Mouret-Reynier MA, Durando X, Van Praagh I, Al-Sukhun S, Ferriere JP, Chollet P (2009). Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin Pharmacother, 10, 1435-47.
DOI
|
24 |
National List of Essential Medicine Development Subcomittee. (2010). Thai national formulary: special access medicines of national list of essential medicines, [Epub ahead of print].
|
25 |
Pasqualetti G, Ricci S, Boni G, et al (2012). Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis. Recent Pat Endocr Metab Immune Drug Discov, 6, 171-6.
DOI
|
26 |
Regan MM, Neven P, Giobbie-Hurder A, et al (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptorpositive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol, 12, 1101-8.
DOI
ScienceOn
|
27 |
Scott LJ, Keam SJ (2006). Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. Drugs, 66, 353-62.
DOI
|
28 |
Shaw HS, Ellis MJ (2002). Letrozole in the treatment of breast cancer. Expert Opin Pharmacother, 3, 607-17.
DOI
|
29 |
Siddiqua A, Tabassum N, Firdous S, Tabassum K (2014). Drug utilization evaluation of anti cancer drugs. Am J Pharmtech Res, 4, 690-702.
|